US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NYSE
XAI Floating Rate and Alternative Income Trust (XFLT) 銘柄情報

XAI Floating Rate and Alternative Income Trust (XFLT)

17.55

-0.38

(-2.12%)

終了 6月16日 5:00AM

17.54

0.00

(0.00%)

取引時間後: 5:00AM

XAI Floating Rate and Alternative Income Trust (XFLT) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

17.55

( -2.12% )

買値

-

売値

-

出来高

90,067

17.48 日の範囲 17.81

2.985 52 週間の範囲 19.48

前日終値

17.93

始値

17.69

時刻

最終取引時間

平均取引量 (3 か月)

94,907

財務取引量

US$ 1,587,176

VWAP

17.6222

Form N-CSRS - Certified Shareholder Report, Semi-Annual

XAI Octagon Floating Rate & Alternative Income Trust Declares its Monthly Common Shares Distribution of $0.225 per Share

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- XAI Octagon Floating Rate & Alternative Income Trust (the...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

XA Investments Launches Custom GenAI Tool for Interval Fund Market Research

CHICAGO, May 20, 2026 (GLOBE NEWSWIRE) -- XA Investments LLC, a Chicago-based alternative investment...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

XA Investments to Become Adviser to Evanston Capital Alternative Investment Fund and Retain Evanston as Portfolio Manager

CHICAGO, May 05, 2026 (GLOBE NEWSWIRE) -- XA Investments LLC (“XAI”), an alternative investment management...

XAI Octagon Floating Rate & Alternative Income Trust Declares its Monthly Common Shares Distribution of $0.225 per Share

CHICAGO, May 01, 2026 (GLOBE NEWSWIRE) -- XAI Octagon Floating Rate & Alternative Income Trust (the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.53	-2.9314159292	18.08	18.39	17.54	59721	18.0014367	CS
4	-1.56	-8.16326530612	19.11	19.155	17.54	71224	18.45956018	CS
12	1.45	9.00621118012	16.1	19.48	15.5401	94907	17.88445512	CS
26	13.03	288.274336283	4.52	19.48	2.985	422889	5.42083946	CS
52	11.91	211.170212766	5.64	19.48	2.985	516763	5.26346238	CS
156	10.95	165.909090909	6.6	19.48	2.985	463830	6.18258082	CS
260	8.27	89.1163793103	9.28	19.48	2.985	358199	6.56446113	CS

XFLT - Frequently Asked Questions (FAQ)

What is the current XAI Floating Rate and Alternative Income Trust share price?

The current share price of XAI Floating Rate and Alternative Income Trust is US$ 17.55

What is the 1 year trading range for XAI Floating Rate and Alternative Income Trust share price?

XAI Floating Rate and Alternative Income Trust has traded in the range of US$ 2.985 to US$ 19.48 during the past year

price_and_volume

price_and_volume 5分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 6分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 7分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 8分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

CV Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a pro

price_and_volume

price_and_volume 10分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 12分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 14分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 15分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 22分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 31分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 33分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 38分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 43分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 43分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 51分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 53分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 54分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

BigBadWolf

BigBadWolf 1時間前

Authorized Shares 1,800,000,000 06/15/2026
Outstanding Shares 1,619,034,363 06/15/2026 >5m
Restricted 480,530,670 06/15/2026 >5m
Unrestricted 1,138,503,693 06/15/2026
Held at DTC 1,011,499,104 06/15/2026 >8m

Authorized Shares 1,800,000,000 06/05/2026

4retire

4retire 1時間前

One has to question why a “cash rich” company would need to raise $20-25 billion by going to bond sales that will be in 7 tranches, ranging from 2 to 30 years. The statement is that it’s for general purposes and to redo some current debt financing.

Based on recent financials, NVDA’

XAI Floating Rate and Al...

1.625% 18jan2029 1.625% ...

EN FR EZ 60EW GR

Alerion Clean Power S.P.A

Aeries Technology

2.36% until 17oct2044 2....

Northwest Biotherapeutics (QB)

Euronext G Veolia 010622...

Newday Partnership Fundi...

Invesco Global Ex US Hig...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。